After a long, strange trip, this CEO is close to taking a psilocybin pill to market
The article profiles Kabir Nath, CEO of Compass Pathways, as his company nears potential FDA approval for COMP360, a psilocybin pill for treatment-resistant depression. It highlights Nath's career shift from traditional pharma to psychedelics and the high stakes involved in this pioneering venture.
Why it matters
This development could revolutionize mental health treatment by introducing a psychedelic-based therapy to the mainstream, potentially offering new hope for patients with severe depression and opening a new frontier in pharmaceutical development.
A lot is riding on the shoulders of Kabir Nath, the CEO of Compass Pathways. Scott Semler for BI Compass Pathways wants to use psilocybin to help people with treatment-resistant depression. Its psilocybin pill, COMP360, could finally be coming to market as soon as next year. For its CEO, Kabir Nath, it's been a long, strange trip to get to this point. In 2022, Kabir Nath had a cushy executive job at a pharmaceutical firm that developed anti-psychotic medication. Then he got a call from a scrappy upstart with a patent on a synthetic version of psilocybin — the active ingredient in magic mushrooms. It hoped to use the compound to help those with treatment-resistant depression. They wanted him to join as CEO. Nath, whose father died by suicide, bit on their second pitch.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in